Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
February 17 2022 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced it will report financial results for
the fourth quarter and full year 2021 and provide a corporate
update at 4:30 p.m. ET on February 28, 2022.
The live call may be accessed by dialing (877) 305-6769 for
domestic callers and (678) 562-4239 for international callers with
conference ID code number: 5169343. A live webcast of the call will
be available online in the investor relations section of Otonomy’s
website at www.otonomy.com and will be archived there for 30
days.
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs with a focus on hearing loss and tinnitus. For
additional information, please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceCate CullenAccount
Director205.910.4443ccullen@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From May 2024 to Jun 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2023 to Jun 2024